Cita APA (7a ed.)
Xiang, Y., Zhang, M., Wang, Q., Liu, J., Zeng, L., Sun, A., & Lu, K. (2025). First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis. Current Oncology, 32(3), 148-160.
Cita Chicago Style (17a ed.)
Xiang, Yan, Meiling Zhang, Qian Wang, Jingwen Liu, Lulin Zeng, Ao Sun, y Kaihua Lu. "First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis." Current Oncology 32, no. 3 (2025): 148-160.
Cita MLA (9a ed.)
Xiang, Yan, et al. "First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis." Current Oncology, vol. 32, no. 3, 2025, pp. 148-160.
Precaución: Estas citas no son 100% exactas.